DA
FDMT icon

Denali Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Denali Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,000
Closed -$34.4K – 491
2023
Q1 		$34.4K Hold
2,000
– – 0.01% 255
2022
Q4 		$44.4K Buy
+2,000
New +$30.9K 0.02% 239

Other funds holding FDMT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Denali Advisors's FDMT Position: Q2 2023 in Review

Denali Advisors sold out of 4D Molecular Therapeutics (FDMT) in Q2 2023, closing a stake of 2,000 shares — an estimated $34.4K sold.

Denali Advisors first reported a position in FDMT in Q4 2022 and held it in 2 quarters. The position peaked at $44.4K in Q4 2022. 100 funds tracked by Wall St. Rank hold FDMT as of Q2 2023.

  • Denali Advisors reported no remaining 4D Molecular Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Denali Advisors sold 2,000 4D Molecular Therapeutics shares in Q2 2023, an estimated $34.4K.
  • Denali Advisors first reported a position in 4D Molecular Therapeutics in Q4 2022 and held it in 2 quarters.
  • Denali Advisors's 4D Molecular Therapeutics position peaked at $44.4K in Q4 2022.
  • 100 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2023.

Based on Denali Advisors's 13F filing for Q2 2023, filed 18 Jul 2023.